- Home
- AIRS vs CLLS Comparison
AIRS vs CLLS Comparison
Compare AIRS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | CLLS |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 476.5M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AIRS | CLLS |
|---|---|---|
| Price | $1.96 | $4.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.75 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 621.4K | 113.0K |
| Earning Date | 11-07-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $157,554,000.00 | $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | $2.55 | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $1.53 | $1.10 |
| 52 Week High | $12.00 | $5.48 |
Technical Indicators
Market Signals| Indicator | AIRS | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 22.66 | 54.14 |
| Support Level | $1.94 | $4.67 |
| Resistance Level | $2.24 | $5.10 |
| Average True Range (ATR) | 0.22 | 0.28 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 0.42 | 56.49 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.